Aptose Biosciences Inc., a clinical-stage biotechnology firm, publicized on Friday that it has priced a public offering of roughly 4.91 million shares at $1.71 per share. This transaction is anticipated to generate nearly $8.4 million. Alongside this, a simultaneous private placement of $4 million with Hanmi Pharmaceutical, Inc. is taking place.
In the context of the private placement, Hanmi is set to purchase shares of Aptose at a rate of $1.90 per share.
In addition, warrants will be issued by Aptose to Hanmi for buying shares at a price of $1.71 per warrant.
The firm conveyed its intentions to allocate the funds raised towards supporting clinical trials, production of clinical supplies, and other corporate-directed initiatives.
Furthermore, Aptose is extending a 30-day option for underwriters to acquire an added 736,842 shares and/or warrants.
The expectation is for this offering to finalize on or near January 30, with the private placement closing approximately a day later, on January 31.
Solely overseeing the transactions as the book-runner is Newbridge Securities Corporation.
Pre-market activity shows a decline in shares of Aptose by 3.66 percent, marking the price at $1.84 on the Nasdaq.
